Brief: Calliditas Estimates Potential Impact Of 3 Months On Previous Timelines With An Expected Decision By EMA In Q1 2022
16/09/2021 14:02
Sept 16 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* CALLIDITAS - WITH REVISED TIMELINE, CO ESTIMATES A
POTENTIAL
IMPACT OF 3 MONTHS ON PREVIOUS TIMELINES WITH AN EXPECTED
DECISION BY EMA IN Q1 2022
* CALLIDITAS THERAPEUTICS - EMA'S CHMP HAS DECIDED TO
CONTINUE
ASSESSMENT OF MAA FOR NEFECON UNDER STANDARD PROCEDURE
ASSESSMENT TIMELINES
Source text for Eikon: ID:nPn7dXxSXa
Further company coverage: CALTX.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations